SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-24-000045
Filing Date
2024-03-13
Accepted
2024-03-13 16:13:01
Documents
17
Period of Report
2024-03-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20240311.htm   iXBRL 8-K 43841
2 EX-4.1 a41_warrantamendment.htm EX-4.1 14704
3 EX-10.1 a101_spa.htm EX-10.1 197644
4 EX-10.2 a102_rra.htm EX-10.2 153925
  Complete submission text file 0001516551-24-000045.txt   602035

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20240311.xsd EX-101.SCH 1923
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20240311_lab.xml EX-101.LAB 20976
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20240311_pre.xml EX-101.PRE 12063
18 EXTRACTED XBRL INSTANCE DOCUMENT skye-20240311_htm.xml XML 2537
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 24746049
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)